Cost Should Be the Principal Determinant of Choice of Erythropoiesis-Stimulating Agent in Chronic Haemodialysis Patients

Publisher： Karger

E-ISSN： 1660-2110|107|1|c14-c19

ISSN： 1660-2110

Source： Nephron Clin Pract, Vol.107, Iss.1, 2007-07, pp. : c14-c19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use and cost of erythropoiesis-stimulating agents in patients with cancer

By Daniel Gregory   Hurley Dana   Whyte Joanna L.   Willey Vincent   Wilson Marcus   Kallich Joel  

Current Medical Research and Opinion, Vol. 25, Iss. 7, 2009-07 ,pp. : 1775-1784

Informa Healthcare

Access to resources Recommend Favorite

Costs Associated with Erythropoiesis-Stimulating Agent Administration to Hemodialysis Patients

By  

Nephron Clin Pract, Vol. 106, Iss. 4, 2007-06 ,pp. : c193-c198

Karger

Access to resources Recommend Favorite

Factors precipitating erythropoiesis‐stimulating agent responsiveness in a European haemodialysis cohort: case‐crossover study

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 24, Iss. 4, 2015-04 ,pp. : 414-426

John Wiley & Sons Inc

Access to resources Recommend Favorite

Time-Dependent Resistance to Erythropoiesis-Stimulating Agent and Mortality in Hemodialysis Patients in the Japan Dialysis Outcomes and Practice Patterns Study

By  

Nephron Clin Pract, Vol. 122, Iss. 1-2, 2013-03 ,pp. : 24-32

Karger

Access to resources Recommend Favorite

High Hemoglobin Levels Maintained by an Erythropoiesis‐Stimulating Agent Improve Renal Survival in Patients with Severe Renal Impairment

By  

THERAPEUTIC APHERESIS AND DIALYSIS, Vol. 19, Iss. 5, 2015-10 ,pp. : 457-465

John Wiley & Sons Inc

Access to resources Recommend Favorite